Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismCYP4V2 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
NGGT001视网膜下腔注射治疗结晶样视网膜变性的I/II期临床研究
[Translation] Phase I/II clinical study of NGGT001 subretinal space injection for the treatment of crystalline retinal degeneration
主要目的评价NGGT001视网膜下腔注射治疗结晶样视网膜变性的安全性和耐受性,推荐后期临床研究的给药剂量。初步探索NGGT001视网膜下腔注射治疗结晶样视网膜变性的有效性。次要目的评价NGGT001视网膜下腔注射后的药物代谢特性。评价NGGT001视网膜下腔注射后机体的免疫反应。
[Translation] The main purpose is to evaluate the safety and tolerability of NGGT001 subretinal space injection in the treatment of crystalline retinal degeneration, and to recommend the dosage for later clinical studies. Preliminary exploration of the effectiveness of NGGT001 subretinal space injection in the treatment of crystalline retinal degeneration. The secondary purpose was to evaluate the drug metabolism properties of NGGT001 after subretinal space injection. To evaluate the body's immune response after NGGT001 injection into the subretinal space.
Clinical Study on the Safety and Efficacy of an Intravenous Infusion of NGGT003 in the Treatment of Hemophilia A
This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT003 in hemophilia A patients. NGGT003 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human FVIII gene B domain deletion mutant (hFVIII BDD), and expresses human FVIII protein in the liver through intravenous injection.
100 Clinical Results associated with Suzhou Nuojiebei Biotechnology Co. Ltd.
0 Patents (Medical) associated with Suzhou Nuojiebei Biotechnology Co. Ltd.
100 Deals associated with Suzhou Nuojiebei Biotechnology Co. Ltd.
100 Translational Medicine associated with Suzhou Nuojiebei Biotechnology Co. Ltd.